Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
The market cap of the other company operating in this Brazilian home grown fertilizer space that is listed on the Canadian stock exchange and is only a little bit ahead of Harvest timing wise is curently $337 million which translates to £223.71 million sterling.
This has got a very long way further to go, without fertilizers the Brazilian plant based economy which feeds so much of the world will falter. There is now a perfect storm of lack of imported supply, increased shipping costs and increased pricing. Now that locally based Harvest are approved as a fertilizer by the Brazilian government extraction should continue apace and go on increasing. The sky really is the limit here.
Personally I believe that one of these days we will all wake up to find that the entire thing has been taken over lock stock and barrel by a major for a very significant unexpectedly large amount of money. At which point it will not be possible to "add more" as it will just be a done deal.
The opportunity for investors here is among the most extraordinary I have ever seen and certainly the most extraordinary in the mining sector in which the London market is meant to specialise. Bo summarises this very well in the short recent presentation. What does $1.4 trillion even look like? I had to look it up. Oh yes $1,400,000,000,000.
https://hk.morningstar.com/ap/PRNewswire/Default.aspx?CLANG=EN-US&rkey=20220109AE19760&filter=3106
The Baltic Exchange ain't no slouch!
When will our journalists actually get educated about what is possible to trust and what is not? https://www.theguardian.com/world/2021/dec/13/can-you-trust-a-negative-lateral-flow-covid-test?CMP=Share_AndroidApp_Other
It is far better news than that! The US healthcare market is dominated by Medicare and this approval for reimbursement is very significant in terms of helping a lot to cover the almost endless healthcare costs older people face in the US.
What possible justification could there be for an 11.74% drop in price within half an hour of opening for this stock which has nothing but positives going for it? Time to complain to the FDA methinks. I am just so fed up with the corruption and instability that dogs these markets.
I couldnt agree more. And the reason why they are putting in so much of their money is because the potential here is clearly and definitely off the scale and making that potential actual with the tools and the money and the people they have is not very hard.
I wonder if anyone else here has paid a visit to our new partners' website and had a good look around at the very large team of utterly brilliant people who we are now in bed with? No wonder our CEO bought a good tranche of shares. I bet he can hardly believe it himself. Take a look for yourself at https://www.koboldmetals.com/ I would be interested to hear what you think. The sheer quality of the team they have put together is extraordinary. There cannot be anything else like this in the whole world of mining. I am awestruck!
Bill Gates-backed KoBold funding Bluejay battery metals mine in Greenland
An Aim-quoted mining company with rights to explore in Greenland has struck a “transformative” deal with a group backed by Bill Gates to drill for metals used in electric vehicle batteries.
Bluejay Mining said that KoBold Metals, backed by the Microsoft billionaire’s Breakthrough Energy Ventures, would fund up to $15 million of drilling in its Disko-Nuussuaq licence area using its “data-led exploration techniques”. In return KoBold, which is based in California, will take a 51 per cent stake in the licence, which spans nearly 3,000 sq km of central west Greenland.
Bluejay believes that the Disko project could contain huge deposits of copper, cobalt and nickel — metals that are in increasing demand for use in batteries.
Breakthrough, chaired by Gates, counts many of the world’s most prominent billionaires among its investors, including Jeff Bezos, the founder of Amazon, Sir Richard Branson, Virgin’s founder, Jack Ma, the chairman of Alibaba, and Masayoshi Son, SoftBank’s founder. KoBold’s other big shareholders include Equinor, the Norwegian state oil group.
Kurt House, KoBold’s chief executive, said that the Disko region had experienced “the rare convergence of events in Earth’s history that could have resulted in forming a world-class battery metal deposit”.
Bluejay has no revenues and reported a £2.5 million pre-tax loss last year. Its biggest shareholders are Sand Grove, M&G and Roderick McIllree, 47, its chairman. It also has a significant retail shareholder base. Its primary focus has been its Dundas project in Greenland, where it wants to mine ilmenite, a source of titanium dioxide, a white pigment used in paints and paper.
Bluejay bought an initial interest in Disko from Cairn Energy in 2017 and has expanded its position. It had planned to drill at Disko last year, but was derailed by the pandemic. McIllree said it was hoped that drilling could commence next year and he shrugged off concerns of opposition to mining in Greenland, saying that it was “one of the pillars that Greenland sees as being the financial part of their independence” from Denmark.
Bluejay’s stake in Disko will be further diluted if it does not match KoBold’s investment after the initial $15 million. McIllree said that the largest potential ore body would require “an enormous amount of capital” to develop, but that if the drilling confirmed a discovery then “our ability to fund this will be very simple”.Monday August 09 2021, 12.01am, The Times
Extracts from a letter received today from my MP: "As you know, on 17 June, the Government set out new proposed laws to validate the accuracy of private coronavirus tests, aimed at making it easier for individuals and business to buy good quality tests with the confidence that the results will be as accurate as possible.
"It is my understanding that this new legislation will mean all private coronavirus tests must pass through a new rigorous and efficient validation process to ensure that they will give reliable results. While I agree that these proposals are welcome, I appreciate you raising your concerns regarding the decision taken by the Department of Health and Social Care to exempt tests currently supplied to the NHS under the department's existing procurement policy.
"Indeed, the Government's testing track record is poor. They hastily procured millions of Innova tests, but soon found out through their own mass-scale trial in Liverpool last year that they failed to pick up 60% of coronavirus infections. The tests also failed to detect 30% of people with high viral loads. Yet despite this, and numerous warnings from experts about the tests' inaccuracy and the need to properly communicate this potential risk to the public, the Government pressed ahead creating a false sense of security for many people who use these rapid tests. Exempting these tests from the new standards is reckless and could result in continually high rates of transmission.
"With more effective rapid testing now more easily available, the Government must face their previous errors and be transparent."
In an RNS 8 March 2021 Dr Alastair Smith, Chief Executive of Avacta Group commented: "We are pleased to confirm that Avacta's rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK. We have also shown that our test detects the D614G variant, the current dominant global strain.
We will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us. Since the Affimer reagents we use in Avacta's range of SARS-CoV-2 tests do not bind in the region of the spike protein where the dominant mutations appear, we do not anticipate that the performance of the tests will be affected.
Now that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus....."
What is ISO 13485?
ISO 13485 is the medical industry's optimal medical device standard, which ensures that all medical devices meet the proper regulatory compliance laws and customer needs. ISO 13485 certification is a valuable credential put in place to keep professionals and customers safe in clinics, hospitals and other medical settings.
ISO 13485:2016 is based on the ISO 9001 process model approach and is a management systems standard specifically developed for the manufacture of medical devices. Its primary objective is to facilitate harmonised medical device regulatory requirements. The standard contains specific requirements for manufacture, installation and servicing of medical devices and calls for:
Implementation of a Quality Management System with several enhancements
Risk Management approach to product development and product realisation
Validation of processes
Compliance with statutory and regulatory requirements
Effective product traceability and recall systems
This standard allows companies to reduce safety and legal risks while creating more economical work environments. As an internationally recognised standard of quality and safety for medical device manufacturing, having ISO 13485 certification helps companies get recognised as more reputable, trustworthy providers. The most recent version of ISO 13485 is reviewed every five years and revised according to the new requirements and needs of the industry.
ISO 13485 has seen a 33.1% increase in worldwide certificates in 2020, showing the growth and importance of UKAS accredited certification in recent times.